Quality | 2009.12.16
Seaside Therapeutics Appoints Tanya Lewis to the Key Position of Vice President, Regulatory Affairs and Quality Assurance
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seaside Therapeutics LLC announced today the appointment of Tanya N. Lewis to the position of Vice President, Regulatory Affairs and Quality Assurance. "Seaside continues to make significant progress in the clinic with two Phase 2 studies of STX-209 well underway in Fragile X Syndrome and autism, as well as the recent initiation of the STX107 clinical program which is expected to begin enrolling individuals with Fragile X in the second half of 2010,” said
For more information, please visit
http://www.businesswire.com/news/home/20091216005669/en
